The Flow Cytometry and Cell Sorting Shared Resource exists to provide investigators of the Cancer Center with access to expertise in flow cytometry and cell sorting. Open access to this facility is provided for all Cancer Center members, which obviates the need for individual laboratories to acquire this expertise or technology. Specific applications of this technology include, but are not limited to, analysis of cellular DNA content, multicolor immunofluorescence measurement, assessment of cellular-level calcium flux, detection and quantitation of uptake and efflux of fluorescent dyes, fluorescence in situ hybridization measurements from single cells, and sorting of individual cells or cell sub-populations based on any of these measurements. The facility is equipped with five flow cytometry instruments, including two high-speed cell sorters and three benchtop flow analyzers. The facility?s staff has considerable experience in the field of flow cytometry, and the services provided include consultation with users regarding experimental design and interpretation of results, sample preparation and staining by experienced technologists, processing of samples by experienced operators, and analysis of data and production of various forms of output of results. Users are also provided with access to computer workstations and flow cytometry software for data analysis. The projected total budget for this Shared Resource in year -25 of this grant is $566,395, of which 40.3% ($228,491) is requested from the CCSG; the remainder of the budget (59.7%, $337,904) will be provided by SJCRH institutional funds and by chargeback to individual investigators. More than 90% of the usage of this Shared Resource is by Cancer Center members for peer-reviewed funded projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA021765-25S1
Application #
6602684
Study Section
Project Start
2002-06-24
Project End
2007-02-28
Budget Start
Budget End
Support Year
25
Fiscal Year
2002
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Scott, Jessica M; Li, Nan; Liu, Qi et al. (2018) Association of Exercise With Mortality in Adult Survivors of Childhood Cancer. JAMA Oncol 4:1352-1358
Rong, Yongqi; Bansal, Parmil K; Wei, Peng et al. (2018) Glycosylation of Cblns attenuates their receptor binding. Brain Res 1694:129-139
Levine, Jennifer M; Whitton, John A; Ginsberg, Jill P et al. (2018) Nonsurgical premature menopause and reproductive implications in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer 124:1044-1052
Li, Jian-Feng; Dai, Yu-Ting; Lilljebjörn, Henrik et al. (2018) Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proc Natl Acad Sci U S A 115:E11711-E11720
Sharma, Akshay; Kang, Guolian; Sunkara, Anusha et al. (2018) Haploidentical Donor Transplantation Using a Novel Clofarabine-containing Conditioning Regimen for Very High-risk Hematologic Malignant Neoplasms. J Pediatr Hematol Oncol 40:e479-e485
Waszak, Sebastian M; Northcott, Paul A; Buchhalter, Ivo et al. (2018) Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol 19:785-798
Zheng, Wenting; O'Hear, Carol E; Alli, Rajshekhar et al. (2018) PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells. Leukemia 32:1157-1167
Heikamp, Emily B; Pui, Ching-Hon (2018) Next-Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia. J Pediatr 203:14-24.e2
Sadighi, Zsila S; Curtis, Elizabeth; Zabrowksi, Jennifer et al. (2018) Neurologic impairments from pediatric low-grade glioma by tumor location and timing of diagnosis. Pediatr Blood Cancer 65:e27063
Wierdl, Monika; Tsurkan, Lyudmila; Chi, Liying et al. (2018) Targeting ALK in pediatric RMS does not induce antitumor activity in vivo. Cancer Chemother Pharmacol 82:251-263

Showing the most recent 10 out of 6764 publications